Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, has announced that it has published a new corporate presentation and investor factsheet.

The corporate presentation outlines Aptamer’s strategy, operational progress and financial performance, offering a comprehensive overview of the Group’s growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

No new material information has been disclosed in either of these publications.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

Aptamer Group secures £270k in new orders and first cash licensing receipts

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence.

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

Aptamer Group AGM statement highlights contract wins and growing order book

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.

    Search

    Search